Brand Name
Adstiladrin
Generic Name
Nadofaragene Firadenovec-Vncg
View Brand Information FDA approval date: September 05, 2023
Form: Suspension
What is Adstiladrin (Nadofaragene Firadenovec-Vncg)?
ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin -unresponsive non-Muscle Invasive Bladder Cancer with carcinoma in situ with or without papillary tumors. ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment